文献速递胸部肿瘤

负载microRNA的微小细胞治疗复发性恶性胸膜间皮瘤的安全性与活性:首次人体1期开放标签剂量递增研究

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
PubMed 文献 · Lancet Oncol · 2017-09-01

该首次人体1期开放标签剂量递增研究在澳大利亚悉尼三个癌症中心纳入27例复发性恶性胸膜间皮瘤患者,26例接受至少一次TargomiRs(负载miR-16模拟物的EGFR靶向微小细胞)输注。确定最大耐受剂量为每周一次5×10^9个TargomiRs;22例可评估疗效者中1例(5%)部分缓解,15例(68%)疾病稳定,中位总生存200天(95%CI 94-358)。

要点

  • TargomiRs最大耐受剂量为每周一次5×10^9个,剂量限制性毒性包括输注相关炎症症状、冠脉缺血、过敏反应、心肌病和非心脏性疼痛。
  • 22例可评估患者中客观缓解率为5%(1例部分缓解),疾病控制包括15例(68%)稳定和6例(27%)进展。
  • 中位总生存为200天(95%CI 94-358),治疗期间发生21例死亡,其中20例与肿瘤进展相关。

核心结论

  • TargomiRs在恶性胸膜间皮瘤患者中显示出可接受的安全性特征和早期活性迹象,支持将其与化疗或免疫检查点抑制剂联合进行进一步研究。

研究设计与样本

  • 首次人体、开放标签、剂量递增1期试验,在澳大利亚悉尼三个主要癌症中心开展。
  • 纳入年龄≥18岁、确诊恶性胸膜间皮瘤、有可测量病灶、既往化疗后影像学进展、ECOG体能状态0或1、预期寿命≥3个月、肿瘤EGFR表达免疫组化阳性且骨髓、肝、肾功能足够的患者。
  • 采用传统3+3剂量递增设计,五个剂量队列,计划剂量递增为5×10^9、7×10^9和9×10^9个TargomiRs每周一次或两次(间隔3天);分析前8例患者数据后,后续所有患者均以1×10^9个TargomiRs开始方案治疗。
  • 主要终点为确定剂量限制性毒性定义的最大耐受剂量、最佳给药频率、客观缓解率、缓解持续时间、至缓解时间和总生存。
  • 分析基于全分析集原则,纳入每例接受至少一剂TargomiRs的患者;研究于2017年1月3日停止入组,注册号NCT02369198和ACTRN12614001248651。

主要发现

  • 2014年9月29日至2016年11月24日共入组27例患者,26例接受至少一剂TargomiRs(1例在治疗开始前死亡)。
  • 共观察到5例剂量限制性毒性:每周两次5×10^9组2例分别出现输注相关炎症症状和冠脉缺血;每周一次5×10^9但接受减量地塞米松预防组2例分别出现过敏反应和心肌病;每周一次5×10^9组1例出现非心脏性疼痛。
  • 确定最大耐受剂量为每周一次5×10^9个TargomiRs。
  • TargomiRs输注伴随一过性淋巴细胞减少(26例中25例,96%)、暂时性低磷血症(26例中17例,65%)、天冬氨酸氨基转移酶或丙氨酸氨基转移酶升高(26例中6例,23%)和碱性磷酸酶血浓度升高(26例中2例,8%)。
  • 5例发生心脏事件:3例心电图改变、1例缺血、1例Takotsubo心肌病。

关键数值与推荐

  • 最大耐受剂量为每周一次5×10^9个TargomiRs。
  • 客观缓解率(完全或部分缓解)为22例中1例(5%)。
  • 疾病稳定15例(68%),疾病进展6例(27%)。
  • 中位总生存200天(95%CI 94-358)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma. METHODS: In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function. Patients were given TargomiRs via 20 min intravenous infusion either once or twice a week (3 days apart) in a traditional 3 + 3 dose-escalation design in five dose cohorts. The dose-escalation steps planned were 5 × 109, 7 × 109, and 9 × 109 TargomiRs either once or twice weekly, but after analysis of data from the first eight patients, all subsequent patients started protocol treatment at 1 × 109 TargomiRs. The primary endpoints were to establish the maximum tolerated dose of TargomiRs as measured by dose-limiting toxicity, define the optimal frequency of administration, and objective response (defined as the percentage of assessable patients with a complete or partial response), duration of response (defined as time from the first evidence of response to disease progression in patients who achieved a response), time to response (ie, time from start of treatment to the first evidence of response) and overall survival (defined as time from treatment allocation to death from any cause). Analyses were based on the full analysis set principle, including every patient who received at least one dose of TargomiRs. The study was closed for patient entry on Jan 3, 2017, and registered with ClinicalTrials.gov, number NCT02369198, and the Australian Registry of Clinical Trials, number ACTRN12614001248651. FINDINGS: Between Sept 29, 2014, and Nov 24, 2016, we enrolled 27 patients, 26 of whom received at least one TargomiR dose (one patient died before beginning treatment). Overall, five dose-limiting toxicities were noted: infusion-related inflammatory symptoms and coronary ischaemia, respectively, in two patients given 5 × 109 TargomiRs twice weekly; anaphylaxis and cardiomyopathy, respectively, in two patients given 5 × 109 TargomiRs once weekly but who received reduced dexamethasone prophylaxis; and non-cardiac pain in one patient who received 5 × 109 TargomiRs once weekly. We established that 5 × 109 TargomiRs once weekly was the maximum tolerated dose. TargomiR infusions were accompanied by transient lymphopenia (25 [96%] of 26 patients), temporal hypophosphataemia (17 [65%] of 26 patients), increased aspartate aminotransferase or alanine aminotranferase (six [23%] of 26 patients), and increased alkaline phosphatase blood concentrations (two [8%]). Cardiac events occurred in five patients: three patients had electrocardiographic changes, one patient had ischaemia, and one patient had Takotsubo cardiomyopathy. Of the 22 patients who were assessed for response by CT, one (5%) had a partial response, 15 (68%) had stable disease, and six (27%) had progressive disease. The proportion of patients who achieved an objective response was therefore one (5%) of 22, and the duration of the objective response in that patient was 32 weeks. Median overall survival was 200 days (95% CI 94-358). During the trial, 21 deaths occurred, of which 20 were related to tumour progression and one was due to bowel perforation. INTERPRETATION: The acceptable safety profile and early signs of activity of TargomiRs in patients with malignant pleural mesothelioma support additional studies of TargomiRs in combination with chemotherapy or immune checkpoint inhibitors. FUNDING: Asbestos Diseases Research Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017. PMID: 28870611. doi:10.1016/S1470-2045(17)30621-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。